Menu

Experimental Ebola Treatments Approved for Use in Uganda

The announcement comes as the country prepares for possible spread of the virus from Democratic Republic of Congo.

Jun 19, 2019
Catherine Offord

ABOVE: An Ebola treatment center in Democratic Republic of Congo’s North Kivu Province, where the latest outbreak began
FLICKR, MONUSCO PHOTOS

Health authorities in Uganda have approved the use of three experimental treatments against Ebola in the country. The decision comes in anticipation of spillover from an ongoing outbreak in neighboring Democratic Republic of Congo and after the deaths of two people in Uganda last week who had traveled across the border from DRC with the virus. 

Reuters reports that the treatments, all of which are already being used DRC, will be shipped to Uganda so that health workers can respond to any further infections. So far, there have been no cases of Ebola spread between people within the country.

See “Three Ebola Cases Identified in Uganda

Uganda’s Health Minister, Jane Ruth Aceng, tweeted the news on Monday: “Happy to inform you all that we got clearance from both Uganda National Council for Science and Technology and National Drug Authority to bring in the Therapeutic treatment for #Ebola patients in the country.”

The drugs include the antibodies ZMapp (made by Mapp Biopharmaceuticals) and REGN-EB3 (made by Regeneron Pharmaceuticals), as well as Gilead Sciences’s antiviral Remdesivir, which was recently shown to work by disrupting viral genome synthesis.

All of the treatments have been in use in DRC since last fall. Protocols for a fourth treatment are underway, World Health Organization (WHO) spokesman Tarik Jasarevic wrote in an email to Reuters

See “Q&A: Anthony Fauci Describes an Experimental Ebola Treatment

The latest outbreak of Ebola began last August and has so far killed more than 1,400 people in DRC, making it the second worst outbreak of the virus after the West African outbreak that killed more than 11,000 people between 2014 and 2016. 

WHO last week (June 14) reaffirmed its decision not to declare an international emergency on the grounds that an announcement could damage the region’s economy and aid efforts.

In the third meeting on the topic since the outbreak began, “it was the view of the committee that there is really nothing to gain by declaring a public-health emergency of international concern, but there is potentially a lot to lose,” Preben Aavitsland, acting chair of the WHO emergency committee, told a press conference at the time, the Wall Street Journal reports.

See “Ebola Outbreak Not A Global Health Emergency, Declares WHO

October 2019

Brain Fog

Air Pollution May Cause Cognitive Decline

Marketplace

Sponsored Product Updates

Lonza’s MODA-ES™ Platform helps Nephron Pharmaceuticals move from paper to an EBR in nine months - Case study to be presented at 2019 ISPE Annual Meeting 
Lonza’s MODA-ES™ Platform helps Nephron Pharmaceuticals move from paper to an EBR in nine months - Case study to be presented at 2019 ISPE Annual Meeting 
·        Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ES™ EBR Platform to streamline manufacturing compliance reporting· The MODA-ES™ Platform was implemented at Nephron in an aggressive nine-month time frame, improving operational efficiency and enabling a significant product line expansion·        Full results of the collaboration will be co-presented by Lonza and Nephron at the 2019 ISPE Annual Meeting & Expo in Las Vegas, Nevada
Understanding T-cell polyfunctionality: How single cell proteomics data drive CAR-T cell therapy research and development
Understanding T-cell polyfunctionality: How single cell proteomics data drive CAR-T cell therapy research and development
Vladimir Senyukov, Director of BioAnalytical Development at Precision Biosciences, talks about investigating T-cell cytokine production using single cell proteomics in order to unlock the therapeutic potential of allogenic CAR-T cells.
Zymo Research launches new RNA-Seq library prep kit
Zymo Research launches new RNA-Seq library prep kit
Zymo Research is excited to announce the fastest and easiest total RNA-Seq library prep kit that allows users to go from sample to sequencer in a single day!